MedPath

Effect of Right Ventricular Lead Position on Defibrillation Threshold

Not Applicable
Withdrawn
Conditions
Ventricular Tachycardia
Ventricular Fibrillation
Interventions
Procedure: Implantable Cardioverter Defibrillator (ICD)
Registration Number
NCT02844127
Lead Sponsor
OhioHealth
Brief Summary

The purpose of this study is to determine how the position of the right ventricular (RV) coil of an implantable cardioverter defibrillator (apex versus septum) affects the defibrillation threshold; specifically, can defibrillator threshold be improved by implantation site selection.

Detailed Description

The investigators propose a prospective, pseudo-randomized study of patients who are electing to undergo implantation of an implantable cardioverter defibrillator (ICD).

There are two locations in the heart in which ICDs are normally implanted: the apex and the septum. The purpose of this study is to determine whether the ICD performs better in one location or the other, as measured by defibrillation threshold. In this study, both locations will be tested in each patient. The final location will be determined by the implanting physician as the location that is best for the patient.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patient indicates for single-chamber (VR), dual-chamber (DR) or resynchronization CRT-D) implantable defibrillator
  • Left-sided implant
  • Single coil or dual coil (single coil for testing)
  • Age ≥ 18 years of age
  • Ability to consent
  • Medically stable, in the opinion of the implanting physician, to undergo defibrillation safety margin testing
  • Procedure performed under conscious sedation
  • English-speaking
Exclusion Criteria
  • Patient unable to understand and consent to the procedure on his or her own
  • Pregnant or breastfeeding patients
  • New York Heart Association (NYHA) Class IV
  • Patients with pre-existing RV leads
  • Pacemaker dependent
  • Patient medically unstable to undergo defibrillation testing (e.g., high risk for deep sedation; patients that develop respiratory compromise or hemodynamic instability from the sedation)
  • Patients that require general anesthesia instead of conscious sedation
  • Patients <18 years of age
  • Non-English-speaking

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Apex FirstImplantable Cardioverter Defibrillator (ICD)Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
Septum FirstImplantable Cardioverter Defibrillator (ICD)Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
Primary Outcome Measures
NameTimeMethod
Defibrillator thresholdAt the time of each surgery through study completion, or up to 12 months

Defibrillator threshold (DFT) will be determined at the time of implantation for each patient at the apex and the septum. A difference of \>4 joules will be considered clinically significant.

Secondary Outcome Measures
NameTimeMethod
Percentage of patients with improved defibrillation threshold at the septum versus the apexAt the time of each surgery through study completion, or up to 12 months

The percentage of patients that have an improved safety profile from septal implantation versus apical implantation will be calculated. Improved safety profile is defined as a defibrillation threshold increase of \>4 joules.

Trial Locations

Locations (1)

OhioHealth Grant Medical Center

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath